All Issue

2022 Vol.3, Issue 2 Preview Page

Review article

30 June 2022. pp. 53-57
Abstract
Sorry, not available.
Click the PDF button.
References
1
Siegel RL et al., Cancer Statistics, 2021
2
Jung KW et al., Prediction of Cancer Incidence and Mortality in Korea, Cancer Res Treat, 2021 10.4143/crt.2021.29033735558PMC8053854
3
Tran J et al., Clinical Review on the Management of Metastatic Renal Cell Carcinoma, JCO Oncol Pract, 2022 10.1200/OP.21.0041934529499
4
Hutson T et al., The Current and Evolving Therapeutic Paradigm in the Management of Metastatic Renal Cell Carcinoma, Kidney Cancer Journal, 2021 10.52733/kcj19n3-r1
5
Motzer RJ et al., Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N Engl J Med, 2018
6
Motzer RJ et al., Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC), Ann Oncol, 2021 10.1016/j.annonc.2021.08.057
7
Rini BI et al., Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N Engl J Med, 2019 10.1056/NEJMoa181671430779529
8
Gabrilovich DI et al., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells, Nat Med, 1996 10.1038/nm1096-10968837607
9
Motz GT et al., Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors, Nat Med, 2014 10.1038/nm.354124793239PMC4060245
10
Voron T et al., VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors, J Exp Med, 2015 10.1084/jem.2014055925601652PMC4322048
11
Rini BI et al., Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426, J Clin Oncol, 2021 10.1200/JCO.2021.39.15_suppl.4500
12
Choueiri TK et al., Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N Engl J Med, 2021 10.1056/NEJMoa202698233657295PMC8436591
13
Motzer R et al., Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma, N Engl J Med, 2021
Information
  • Publisher :The Association of Korean Urologists
  • Publisher(Ko) :대한비뇨의학과의사회
  • Journal Title :비뇨의학 Urology Digest
  • Volume : 3
  • No :2
  • Pages :53-57